 Potassium Channel Blockers
"Potassium Channel Blockers" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A class of drugs that act by inhibition of potassium efflux through cell membranes. Blockade of potassium channels prolongs the duration of ACTION POTENTIALS. They are used as ANTI-ARRHYTHMIA AGENTS and VASODILATOR AGENTS.
| Descriptor ID |
D026902
|
| MeSH Number(s) |
D27.505.519.562.500 D27.505.954.411.645
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Potassium Channel Blockers".
Below are MeSH descriptors whose meaning is more specific than "Potassium Channel Blockers".
This graph shows the total number of publications written about "Potassium Channel Blockers" by people in this website by year, and whether "Potassium Channel Blockers" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1993 | 1 | 0 | 1 | | 1996 | 0 | 1 | 1 | | 1999 | 0 | 1 | 1 | | 2001 | 0 | 1 | 1 | | 2002 | 0 | 1 | 1 | | 2003 | 0 | 2 | 2 | | 2005 | 0 | 1 | 1 | | 2008 | 0 | 1 | 1 | | 2009 | 0 | 1 | 1 | | 2010 | 0 | 1 | 1 | | 2012 | 1 | 1 | 2 | | 2013 | 0 | 2 | 2 | | 2014 | 0 | 1 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 0 | 1 | | 2017 | 0 | 1 | 1 | | 2019 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Potassium Channel Blockers" by people in Profiles.
-
Aretz CD, Vadukoot AK, Hopkins CR. Discovery of Small Molecule Renal Outer Medullary Potassium (ROMK) Channel Inhibitors: A Brief History of Medicinal Chemistry Approaches To Develop Novel Diuretic Therapeutics. J Med Chem. 2019 10 10; 62(19):8682-8694.
-
Modrak M, Sundem L, Gupta R, Zuscik MJ, Elfar J. Pharmacological Attenuation of Electrical Effects in a Model of Compression Neuropathy. J Bone Joint Surg Am. 2019 Mar 20; 101(6):523-530.
-
Guo A, Niyazov A, Macaulay D, Terasawa E, Schmerold L, Wu EQ, Krieger S. Inpatient Admissions and Costs Associated with Persistent Use of Dalfampridine Extended-Release in Multiple Sclerosis: A Claims Database Analysis. J Manag Care Spec Pharm. 2017 Jul; 23(7):771-780.
-
Tseng KC, Li H, Clark A, Sundem L, Zuscik M, Noble M, Elfar J. 4-Aminopyridine promotes functional recovery and remyelination in acute peripheral nerve injury. EMBO Mol Med. 2016 12; 8(12):1409-1420.
-
Holdsworth CT, Ferguson SK, Poole DC, Musch TI. Modulation of rat skeletal muscle microvascular O2 pressure via KATP channel inhibition following the onset of contractions. Respir Physiol Neurobiol. 2016 Feb 01; 222:48-54.
-
Simpson DM, Goldenberg J, Kasner S, Nash M, Reding MJ, Zweifler RM, Suarez G, Zhao P, Henney HR, Rabinowicz AL, Carrazana E. Dalfampridine in chronic sensorimotor deficits after ischemic stroke: A proof of concept study. J Rehabil Med. 2015 11; 47(10):924-31.
-
Shiraishi T, Tamura Y, Taniguchi K, Higaki M, Ueda S, Shima T, Nagura M, Nakagawa T, Johnson RJ, Uchida S. Combination of ACE inhibitor with nicorandil provides further protection in chronic kidney disease. Am J Physiol Renal Physiol. 2014 Dec 15; 307(12):F1313-22.
-
Robbins J, Passmore GM, Abogadie FC, Reilly JM, Brown DA. Effects of KCNQ2 gene truncation on M-type Kv7 potassium currents. PLoS One. 2013; 8(8):e71809.
-
Reilly JM, Telezhkin V, Passmore GM, Marsh SJ, Brown DA. Kv7/M-type potassium channels in rat skin keratinocytes. Pflugers Arch. 2013 Sep; 465(9):1371-81.
-
Egeberg MD, Oh CY, Bainbridge JL. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances. Clin Ther. 2012 Nov; 34(11):2185-94.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|